Synopsis of recent research by authors named "Yinying Lu"
- Yinying Lu's recent research focuses on the role of host-targeted therapies and biomarkers in the treatment of viral infections and cancers, especially emphasizing the significance of vascular endothelial growth factor receptor (VEGFR) inhibitors and immune checkpoint inhibitors for improving clinical outcomes in diseases like enterovirus infections and hepatocellular carcinoma (HCC).
- Key findings from her studies include the identification of Rho-associated coiled-coil-containing protein kinase as a novel host factor for enterovirus replication, as well as the establishment of a large organoid biobank for liver cancer that aids in understanding tumor heterogeneity and drug sensitivity.
- Additionally, Lu's work highlights the potential of novel therapies such as proteolysis-targeting chimeras (e.g., PJ-001) in managing conditions like atopic dermatitis and their role in mediating immune responses in various cancer metastases, thereby encompassing a broad spectrum of therapeutic applications across oncology and immunology.
